LinkedIn facebook twitter youtube

A qualitative study of the perspectives of myeloma patients and health care professionals on Minimal Residual Disease (MRD) status as an endpoint for Multiple Myeloma in clinical trials and in treatment decision making


Project Launch: April 2022


The study aims to gain a deeper understanding of the patient experience and perspective of using minimal residual disease (MRD) status both in clinical trials as a primary endpoint and in health technology and regulatory assessments, and as part of treatment decision making.


The broad research questions/aims of the study are to understand:


  • Are patients aware of and educated on MRD?
  • What is their perspective on its importance?
  • Role of MRD in regulatory and health technology assessment decisions?
  • Impact on treatment decisions from clinicians and health care professionals
  • Perspectives of patients and health care professionals from different European countries
  • Impact on emotional wellbeing of knowing MRD status
  • What are the challenges around MRD testing?


The outputs of this project will advance and expand our knowledge of patients’ and clinicians’ perspectives of MRD, which will inform future research and highlight needs for educational related to this topic.

This project will be managed and conducted by MPE.


Recruitment status: Predicted to begin mid-June


If you would like to participate in this research, please email research@mpeurope.org and we will be in touch when we start recruitment.